Sugammadex Versus Neostigmine in Patients With Liver Cirrhosis Undergoing Liver Resection

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

August 31, 2015

Study Completion Date

September 30, 2015

Conditions
Cirrhosis and Chronic Liver Disease
Interventions
DRUG

Sugammadex

Rocuronium-induced neuromuscular blockade will be reversed at the end of the operation when two responses to train-of-four ulnar nerve stimulation are detected (T2) by injection of sugammadex 2mg/kg.

DRUG

Neostigmine

Rocuronium-induced neuromuscular blockade will be reversed at the end of the operation when two responses to train-of-four ulnar nerve stimulation are detected (T2) by injection of neostigmine 50 micro-gram/kg combined with atropine 20 micro-gram/kg.

DRUG

Rocuronium

An intubating dose of Rocuronium (0.6 mg/kg) will be given with induction of anesthesia and the degree of muscle relaxation will be evaluated through out the operation by recording the response of the hand muscles to train-of-four ulnar nerve stimulator (Mechanosensor Neuromuscular Transmission Module of General Electric AISYS Anaesthesia machine USA) according to the Good Clinical Research Practice (GCRP) guidelines for pharmacodynamic neuromuscular studies. Muscle relaxation will be maintained by additional top-up doses of Rocuronium (0.15mg/kg) which will be administered after detection of the first response to TOF stimulation (T1).

Trial Locations (1)

11562

National Liver institute, Ḩadā’iq al Qubbah

All Listed Sponsors
collaborator

National Liver Institute, Egypt

OTHER

lead

Cairo University

OTHER

NCT02414880 - Sugammadex Versus Neostigmine in Patients With Liver Cirrhosis Undergoing Liver Resection | Biotech Hunter | Biotech Hunter